ProfileGDS5678 / 1428973_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 94% 93% 92% 93% 94% 93% 94% 94% 92% 93% 93% 91% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8924593
GSM967853U87-EV human glioblastoma xenograft - Control 28.1906294
GSM967854U87-EV human glioblastoma xenograft - Control 37.9374293
GSM967855U87-EV human glioblastoma xenograft - Control 47.888792
GSM967856U87-EV human glioblastoma xenograft - Control 58.0234293
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.9232294
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.5709393
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0060994
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.152594
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.734192
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7230893
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.8845293
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.416891
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9040393